Li et al. reported, in 2019, that artemether administered at doses of 5 mg/kg or 20 mg/kg, reduced both the Aβ deposition and phosphorylation of tau (Ser 416) by 20–40% in the brain cortex of 10-month-old 3xTg AD mice after treatment for four weeks [82]. Here, MAPT is linked to Alzheimer disease.